Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease
CONCLUSION: Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up.PMID:36216573 | DOI:10.5551/jat.63404
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Authors: Chung-Kuan Wu Chia-Hsun Lin Noi Yar Zih-Kai Kao Ya-Bei Yang Yun-Yi Chen Source Type: research
More News: Angioplasty | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chia | Cilostazol | Databases & Libraries | Dialysis | Emergency Medicine | Health Insurance | Heart | Hemodialysis | Hemorrhagic Stroke | Insurance | Ischemic Stroke | Peripheral Angioplasty | Peripheral Vascular Disease (PVD) | Stroke | Study | Thrombosis